CDKN2A and neoplasm: Variants in 5 genes (RPN1, CDKN2A, HRAS, PALB2, CBFA2T3) have been identified in 32 individuals with tumor from the extended cohort and classified as pathogenic, likely pathogenic, and VUS (Supplementary Table 1).